Akèy › BPCO › Alabama › Birmingham
Etid klinik pou BPCO nan Birmingham, AL
17 etid pou BPCO ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Ap rekriteFaz 4
- University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, Birmingham
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2
- Research Site, Birmingham
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Ap rekriteFaz 2
- University of Alabama, Birmingham
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2/3
- University of Alabama at Birmingham Lung Health Center, Birmingham
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
Ap rekriteFaz 3
- GC2501 Study Site 106, Birmingham
Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
Ap rekriteEtid obsèvasyon
- Cooper Green Mercy Hospital, Birmingham
Multi-Center Clean Air Randomized Controlled Trial in COPD
Ap rekriteFaz 3
- University of Alabama, Lung Health Center, Birmingham
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
Ap rekrite
- The University of Alabama at Birmingham, Birmingham
SPIROMICS Study of Early COPD Progression (SOURCE)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of Alabama at Birmingham, Birmingham
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
Ap rekrite
- University of Alabama-Birmingham Hospital - UAB Lung Health Center, Birmingham
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Ap rekrite
- University of Alabama at Birmingham, Birmingham
PiMZ Longitudinal Cohort (PiMZ Logic)
Ap rekriteEtid obsèvasyon
- University of Alabama at Birmingham, Birmingham
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Ap rekriteFaz 4
- University of Alabama at Birmingham, Birmingham
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Ap rekrite
- UAB School of Medicine/Lung Health Center, Birmingham
Etid BPCO nan lòt vil
- Philadelphia, PA22 etid
- Miami, FL18 etid
- Boston, MA17 etid
- Houston, TX15 etid
- Orlando, FL15 etid
- Chicago, IL14 etid
- Baltimore, MD13 etid
- Dallas, TX12 etid
- Pittsburgh, PA12 etid
- New York City, NY11 etid
- Winston-Salem, NC9 etid
- Charlotte, NC9 etid
Lòt etid nan Birmingham
- Kansè (tout kalite)31 etid
- Kansè nan tete24 etid
- Obèsite23 etid
- Kansè ovè23 etid
- Kansè Poumon ki pa ti selil22 etid
- Leksemi mieloïd egi21 etid
- Myelom Miltip18 etid
- Maladi kadyovaskilè17 etid
- Sipwa16 etid
- Fibroz sistik16 etid
- Kansè Endomèt16 etid
- Dyabèt Tip 216 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.